KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Gastroenterology / 2014 / Cilt: 25 - Sayı: 4

Protein-losing gastropathy caused by mesalamine in a patient with ulcerative colitis

Jae Hyun KİM
Won MOON
Seun Ja PARK
Moo In PARK
Sung Eun KİM
Ki Hwan KU
Sung Eun SONG
Hee Kyung CHANG
Sayfa
106–107
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

KİM, J. H., MOON, W., PARK, S. J., PARK, M. I., KİM, S. E., KU, K. H., SONG, S. E., CHANG, H. K. (2014). Protein-losing gastropathy caused by mesalamine in a patient with ulcerative colitis. Turkish Journal of Gastroenterology, Cilt: 25 - Sayı: 4, 106–107. https://ajindex.com/articles/409552

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996; 10: 949-56. [CrossRef] 2. Fiorentini MT, Fracchia M, Galatola G, Barlotta A, de la Pierre M. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci 1990; 35: 1180-2. [CrossRef] 3. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995; 40: 296-304. [CrossRef] 4. Shimodate Y, Takanashi K, Waga E, Fujita T, Katsuki S, Nomura M. Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis. Case Rep Gastroenterol 2011; 5: 159-65. [CrossRef]